Shares of ReNeuron Group plc (LON:RENE – Get Free Report) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 3.38 ($0.04) and traded as low as GBX 3.28 ($0.04). ReNeuron Group shares last traded at GBX 3.38 ($0.04), with a volume of 177,373 shares.
ReNeuron Group Stock Down 2.2 %
The stock has a market cap of £1.93 million, a P/E ratio of -37.50 and a beta of 0.83. The stock’s 50-day moving average is GBX 3.38 and its 200-day moving average is GBX 3.38. The company has a current ratio of 1.51, a quick ratio of 2.02 and a debt-to-equity ratio of 14.25.
ReNeuron Group Company Profile
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease.
Featured Articles
- Five stocks we like better than ReNeuron Group
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- Consumer Discretionary Stocks Explained
- Williams-Sonoma Stock: Buy It and Never Let It Go
- Utilities Stocks Explained – How and Why to Invest in Utilities
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.
